This entity has not been resolved onto another DFX graph by a shared identifier. A name match elsewhere would be a candidate, never an identity, and none is recorded.

Form D industry group

Biotechnology

Rounds

2

Latest round

Form D equity offering 2026-06-10

Latest round amount

$75.0M

Investors

2

People

2

Incorporated

2019

Revenue range

Decline to Discloseas stated on Form D

• Occurred

  Jun 25, 2026
  Form D filed

  Lycia Therapeutics, Inc. filed Form D: $75,000,000 sold of $75,000,000, Biotechnology

  Form Dobserved 8 days ago
  $75.0M
• Occurred

  May 23, 2024
  Form D filed

  Lycia Therapeutics, Inc. filed Form D: $106,600,004 sold of $106,600,004, Biotechnology

  Form Dobserved 8 days ago
  $107M

Also named here, with no published line of their own (reach them through the firm): Aetna Wun Trombley (Executive Officer/Director), AMY Bachrodt (Executive Officer), William Rieflin (Director), Clare Ozawa (Director), Ming Fang (Director), Ming Fang (Director), Laurent Fischer (Director), TIM Anderson (Director), Andrew Gottesdiener (Director).

Who to call is the organisation, the person's role and the line they published themselves: a business phone, office address, website or profile link from Form ADV, Form 13F or their own website, with that source named on every value. The counts above are what a reveal returns; a personal email is rarely published, so most reveals are the firm's line. Never data bought from a provider, never anything personal. Reveals by plan

Graph

Venture Capital

Canonical id

dfx:vc:b12e9e55-a202-462b-8651-59c791096a97

First observed

Sep 12, 2026

Last observed

Sep 12, 2026 8 days ago

Resolution

Identity across graphs by shared identifier (CRD, CIK, EIN, ADV fund id, individual CRD) or citation; a name match is shown as a candidate and never merged.